Inventor · disambiguated record
Melissa Dumble
Also filed as: DUMBLE MELISSA · DUMBLE MELISSA L
8 granted patents·13 pending applications·30 citations·filing 2010–2024
81Inventor score
Files withPMV PHARMACEUTICALS INC7DUMBLE MELISSA5GLAXOSMITHKLINE LLC4NOVARTIS AG3PTC THERAPEUTICS INC1
Top patents by PatentIndex Score
21 records- 0193US8952018B2Pharmaceutical combination of MEK inhibitor and B-Raf inhibitorsGLAXOSMITHKLINE LLC·Filed 2014·Granted Feb 10, 2015·13 cites·5 claims
- 0291US11938124B2Combination therapy for treatment of cancerPMV PHARMACEUTICALS INC·Filed 2021·Granted Mar 26, 2024·2 cites·28 claims
- 0391US8703781B2Pharmaceutical combination of MEK inhibitor and B-RAF inhibitorsDUMBLE MELISSA·Filed 2010·Granted Apr 22, 2014·14 cites·12 claims
- 0473US2024269126A1Combination therapy for treatment of cancerPMV PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0568US2015111904A1Pharmaceutical combination of mek inhibitor and b-raf inhibitorsGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 0663US8796298B2Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancerDUMBLE MELISSA·Filed 2010·Granted Aug 5, 2014·1 cites·1 claims
- 0763US2024100050A1Mdm2 inhibitors and uses thereofPMV PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0859US2015094321A1CombinationGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 0959US2025319063A1Methods and compounds for restoring mutant p53 functionPMV PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1058US2014309243A1CombinationGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 1156US2018214451A1CombinationNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1255US9402846B2Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancerNOVARTIS AG·Filed 2014·Granted Aug 2, 2016·0 cites·15 claims
- 1355US2021403945A1Compositions and methods utilizing genetically-modified animals and cellsPMV PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1454US12419880B2Companion diagnostic tool for mutant p53 reactivating compoundsPMV PHARMACEUTICALS INC·Filed 2021·Granted Sep 23, 2025·0 cites·16 claims
- 1554US2023049952A1Methods and compounds for restoring mutant p53 functionPMV PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1653US12023335B2Method for treating pancreatic cancerPTC THERAPEUTICS INC·Filed 2019·Granted Jul 2, 2024·0 cites·7 claims
- 1750US2016143913A1CombinationNOVARTIS AG·Filed 2016·Application pending·0 cites
- 1848US2012283278A1CombinationDUMBLE MELISSA·Filed 2010·Application pending·0 cites
- 1945US8835450B2Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancerDUMBLE MELISSA·Filed 2010·Granted Sep 16, 2014·0 cites·4 claims
- 2040US2014323557A1Compounds for the modulation of beta-catenin expression and uses thereofSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 2140US2012322817A1CombinationDUMBLE MELISSA·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Melissa Dumble files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →